Vanda Schizophrenia Drug Patentable, Fed. Circ. Says
A three-judge panel ruled 2-1 that U.S. Patent Number 8,586,610 covers the use of a patient’s genotype to tailor dosage, but it specifically tells doctors how to harness that relationship and use it in treatments rather than just describing the natural factors themselves.
The Mayo decision requires courts to look at...
To view the full article, register now.
Try Law360 FREE for seven days
Already a subscriber? Click here to login